Edesa Biotech, Inc.
EDSA
$4.72
-$0.01-0.21%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 61.88% | 32.50% | 38.43% | 38.22% | -6.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 189.94% | 162.19% | 23.32% | 145.94% | -1.49% |
| Operating Income | -189.94% | -162.19% | -23.32% | -145.94% | 1.49% |
| Income Before Tax | -209.09% | -165.32% | -38.98% | -131.62% | -4.87% |
| Income Tax Expenses | -- | 0.00% | -- | -- | -- |
| Earnings from Continuing Operations | -209.09% | -165.24% | -38.98% | -131.62% | -4.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -209.09% | -165.24% | -38.98% | -131.62% | -4.87% |
| EBIT | -189.94% | -162.19% | -23.32% | -145.94% | 1.49% |
| EBITDA | -192.54% | -164.56% | -24.81% | -154.57% | 0.16% |
| EPS Basic | -140.99% | -64.74% | 41.70% | -6.65% | 51.89% |
| Normalized Basic EPS | -140.98% | -64.76% | 41.69% | 16.46% | 51.89% |
| EPS Diluted | -140.99% | -64.74% | 41.70% | -6.65% | 51.89% |
| Normalized Diluted EPS | -140.98% | -64.76% | 41.69% | 16.46% | 51.89% |
| Average Basic Shares Outstanding | 28.26% | 60.98% | 138.33% | 117.22% | 117.97% |
| Average Diluted Shares Outstanding | 28.26% | 60.98% | 138.33% | 117.22% | 117.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |